Cherry (C3RY) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
4 Feb, 2026Company overview
Operates globally as a developer and manufacturer of high-end input devices and solutions, including hardware, software, and cloud services.
Serves diverse markets: gaming, office, health, and industrial, with significant user bases in each segment.
Signature products include keyboards, mice, microphones, mechanical switches, eHealth terminals, robotics modules, and SaaS for eHealth.
Focuses on user-centric design, customization, ergonomic solutions, and strong client support.
Recognized with multiple international awards for design, innovation, and sustainability.
Business update and transformation
2023 marked a transformation year with group revenue of €126.5m and adjusted EBITDA of €15.2m.
Initiated cost-saving measures, strict cash management, and expanded partnerships in key markets.
Prudent balance sheet adjustments included a €96m impairment and a streamlined financial structure.
Secured €25m credit line with covenant holiday and achieved €5.5m in restructuring benefits.
Q1 2024 showed a strong start with revenue of €30.3m and improved adjusted EBITDA compared to Q1 2023.
Strategy and outlook
2024 targets: revenue of €140m–€150m and EBITDA margin of 7–8%, driven by organic growth and cost management.
Focus on debt reduction, internal financing, and innovation in esports, hybrid work, and healthcare.
Growth expected across all divisions: components, peripherals, and digital health, with new product launches and expanded distribution.
Global market share in keyboard switches expected to recover, and eHealth terminals maintain high market share.
Profitability forecast to increase by approximately 5.9 percentage points year-over-year.
Latest events from Cherry
- 2025 revenue fell 15% to €94.3M, with cost cuts, margin recovery, and segment review ongoing.C3RY
Q4 20255 Mar 2026 - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation4 Feb 2026 - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation4 Feb 2026 - Restructuring, M&A, and operational streamlining target a return to growth and financial stability.C3RY
Investor presentation4 Feb 2026 - Digital Health & Solutions growth and cost controls support outlook despite margin pressure.C3RY
Q2 20243 Feb 2026 - Q3 2024 results missed expectations, triggering restructuring and a cut in full-year guidance.C3RY
Q3 2024 TU19 Jan 2026 - Revenue and margins fell, but Q4 free cash flow rose as restructuring targets 2025 recovery.C3RY
Q4 2024 TU26 Dec 2025 - Restructuring and SaaS focus aim to restore profitability and drive growth in 2025.C3RY
Analyst Day 202525 Nov 2025 - 9M 2025 revenue down 16%, Q3 up 9.3% YoY; net loss widens amid restructuring.C3RY
Q3 2025 TU17 Nov 2025